64 completed, 6 unknown, 5 recruiting, 4 terminated. 20 Phase 2, 16 Phase 3, 14 Not applicable, 10 Phase 4, 8 Phase 1.
Follow Spirurida Infections: new trials by email Literature Review of Spirurida Infections trials Research Report on Spirurida Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Modified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg - Onchocerciasis (River Blindness), Schistosomiasis | Not applicable | Recruiting | Uwemedimo Friday Ekpo | 5760 | 2026-07-01 | 2026-07-16 |
| Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers A mobile app with AI functionality for diagnosing skin-related NTDs - Skin and Connective Tissue Diseases, Neglected Tropical Diseases | Not applicable | Not yet recruiting | Kenya Medical Research Institute | 2420 | 2026-05-01 | 2026-04-02 |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Integrating Mental Health Into Neglected Tropical Disease Care in Ghana WHO Essential Care package for mental health and NTDs - Leprosy, Lymphatic Filariases | Not applicable | Not yet recruiting | Liverpool School of Tropical Medicine | 200 | 2025-11-01 | 2025-11-25 |
| Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases Moxidectin, Ivermectin - Onchocerciasis, Ascaris Lumbricoides Infection | Phase 4 | Recruiting | Kirby Institute | 52000 | 2025-08-04 | 2025-11-21 |
| 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia Albendazole 400mg, Placebo - Loiasis With Positive Blood Microfilaremia, Loiasis | Phase 3 | Not yet recruiting | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 100 | 2025-01-15 | 2024-09-26 |
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination Biological samples collection (blood drawing + feces) - Onchocerciasis, Loiasis | Not applicable | Completed | Bioaster | 1128 | 2024-04-15 | 2026-09-30 |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Assessment and Treatment of Loiasis With Positive Microfilaremia Loiasis With Positive Blood Microfilaremia | Unknown | University Hospital, Angers | 200 | 2024-02-01 | 2024-01-08 | |
| Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study nodulectomy - Onchocercal Subcutaneous Nodule, Epilepsy | Unknown | Universiteit Antwerpen | 40 | 2023-06-01 | 2023-05-22 | |
| Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa LTS-2 DEC patch, Skin snips - Onchocerciasis, Loiasis | Not applicable | Withdrawn | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 2022-09-01 | 2025-03-25 | |
| PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets Oxfendazole, Placebo - Filariasis | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 30 | 2022-04-21 | 2022-12-20 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis | Phase 1 | Terminated | Liverpool School of Tropical Medicine | 30 | 2021-12-10 | 2023-09-21 |
| Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Administration of Albendazole on Day 1, Administration of Ivermectin on Day 1, Administration of Azithromycin on Day 1 - Trachoma, Lymphatic Filariases | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 13511 | 2021-12-01 | 2022-08-19 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events Ivermectin - Loiasis | Phase 4 | Completed | Washington University School of Medicine | 41 | 2021-07-30 | 2022-09-29 |
Showing 20 of 88. Sign in to see all of them.
Elephantiasis, Filarial (41) · Onchocerciasis (35) · Filariasis (23) · Loiasis (12) · Neglected Diseases (11) · Onchocerciasis, Ocular (10) · Parasitic Diseases (6) · Scabies (6) · Coinfection (5) · Epilepsy (5) · Malaria (5) · Mansonelliasis (5) · Yaws (5) · Buruli Ulcer (4) · Helminthiasis (4)
Secernentea Infections (87) · Nematode Infections (86) · Infections (85) · Helminthiasis (84) · Parasitic Diseases (82) · Filariasis (65) · Vector Borne Diseases (52) · Mosquito-Borne Diseases (43) · Hemic and Lymphatic Diseases (42) · Lymphatic Diseases (42) · Skin Diseases (42) · Skin and Connective Tissue Diseases (42) · Skin Diseases, Infectious (40) · Lymphedema (38)
Ivermectin (31) · Albendazole (26) · Diethylcarbamazine (13) · moxidectin (10) · Doxycycline (6) · Albumins (5) · Azithromycin (5) · Bay 44-4400 (5) · Praziquantel (3) · emodepside (3) · Intravital Microscopy (2) · Levamisole (2) · Blood Specimen Collection (1) · Defecation (1) · Imatinib Mesylate (1)
National Institute of Allergy and Infectious Diseases (NIAID) (14) · Washington University School of Medicine (13) · Medicines Development for Global Health (6) · University Hospitals Cleveland Medical Center (6) · Drugs for Neglected Diseases (4) · London School of Hygiene and Tropical Medicine (4) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (3) · The Task Force for Global Health (3) · Universiteit Antwerpen (3) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (2) · Centre d'Appui à la lutte contre la Maladie (2) · DBL -Institute for Health Research and Development (2) · Lihir Medical Centre (2) · Liverpool School of Tropical Medicine (2) · Noguchi Memorial Institute for Medical Research (2)
Ghana (11) · India (10) · Cameroon (7) · Democratic Republic of the Congo (7) · Papua New Guinea (6) · United States (6) · Côte d’Ivoire (5) · Mali (5) · Liberia (4) · United Kingdom (4) · Fiji (3) · Indonesia (3) · Tanzania (3) · Egypt (2) · Ethiopia (2)
Gary Weil, MD (6) · Amy D Klion, M.D. (3) · Eric Ottesen, MD (3) · Gary J Weil, MD (3) · Thomas B Nutman, M.D. (3) · Benjamin Koudou, PhD (2) · Christopher King, MD PhD (2) · Christopher L King, MD, PhD (2) · James W Kazura, MD (2) · Peter U Fischer, PhD (2) · Philip Budge, MD, PhD (2) · Tony Ukety, MD, DO, MPH (2)
PMID 11873261, PMID 22610930, PMID 32228663, PMID 42848323, PMID 10656038, PMID 35533701, PMID 37262040, PMID 18809192, PMID 19081121, PMID 19812401, PMID 23675549, PMID 23981378, PMID 24968000, PMID 25793933, PMID 25877874, PMID 26486704, PMID 26691247, PMID 28061905, PMID 28329346, PMID 28855148, PMID 28969715, PMID 29346377, PMID 29361335, PMID 30403937, PMID 30878222, PMID 31107869, PMID 31233507, PMID 31314757, PMID 31641754, PMID 31923177, PMID 32055862, PMID 32561912, PMID 32818264, PMID 32976514, PMID 33137100, PMID 33674871, PMID 33728462, PMID 33780481, PMID 33930024, PMID 33979325, PMID 34226233, PMID 34281614, PMID 34310218, PMID 34403424, PMID 34651190, PMID 34758017, PMID 35139070, PMID 35476631, PMID 35701056, PMID 35803632
2017 (2), 2015 (1), 2023 (1), R01AI155739 (1)